BR0003375A - 1 2 4 5 -tetraidro-benzo{d}azepinas - Google Patents

1 2 4 5 -tetraidro-benzo{d}azepinas

Info

Publication number
BR0003375A
BR0003375A BR0003375-8A BR0003375A BR0003375A BR 0003375 A BR0003375 A BR 0003375A BR 0003375 A BR0003375 A BR 0003375A BR 0003375 A BR0003375 A BR 0003375A
Authority
BR
Brazil
Prior art keywords
chr
lower alkyl
nitro
alkenyl
ocf
Prior art date
Application number
BR0003375-8A
Other languages
English (en)
Inventor
Geo Adam
Alfred Binggeli
Hans-Peter Marki
Vicent Mutel
Maurice Wilhelm
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0003375A publication Critical patent/BR0003375A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Patente de Invenção: <B>"1,2,4,5-TETRAIDRO-BENZO[D]AZEPINAS"<D>. a presente invenção refere-se a derivados de 1,2,4,5-tetraidrobenzo[d]azepina da fórmula geral em que R^ 1^ significa hidrogênio, alquila inferior, oxigênio, halogênio, ou -OR, -O(C~ 3~-C~ 6~)cicloalquila, -O(CHR)~ n~-(C~ 3~-C~ 6~) cicloalquila, -O(CHR)~ n~CN, -O(CHR)~ n~CF~ 3~, -O(CHR)(CHR)~ n~NR~ 2~, -O(CHR)(CHR)~ n~OR, O(CHR)~ n~-alquenila inferior, -OCF~ 3~, -OCF~ 2~-R, -OCF~ 2~-alquenila inferior, -OCHRF, -OCHF-alquenila inferior, -OCF~ 2~CRF~ 2~Br, -O(CHR)~ n~CF~ 2~Br, -O(CHR)~ n~-fenila, em que o grupo fenila pode estar opcionalmente substituído independentemente entre si por um a três grupos alquila inferior, alcóxi inferior, halogênio, nitro ou ciano, -O(CHR)(CHR)~ n~-morfolino, -O(CHR)(CHR)~ n~-pirrolidino, O(CHR)(CHR)~ n~-piperidino, -O(CHR)(CHR)~ n~-imidazolo, -O(CHR)(CHR)~ n~-triazolo, -O(CHR)~ n~-piridino, -O(CHR) (CHR)~ n~-OSi-alquila inferior, -O(CHR) (CHR)~ n~ OS(O)2-alquila inferior, -O (CH~ 2~)~ n~CH=CF~ 2~, -O(CHR)~ n~-2,2-dimetil-[1.3]dioxolano, -O(CHR)~ n~-CHOR-CH~ 2~OR, -O(CHR)~ n~-CHOR-(CHR)~ n~-CH~ 2~OR ou -SR ou -S(CHR)~ n~COOR, ou -NR^ 2^, -N(R)(CHR)(CHR)~ n~OR, -N(R)(CHR)~ n~CF~ 3~, -N(R) (CHR(CHR)~ n~-morfolino, -N(R)(CHR)(CHR)~ n~-imidazolo, -N(R)(CHR)(CHR)~ n~-pirrolidino, -N(R)(CHR)(CHR)~ n~-pirrolidin-2-ona, -N(R) (CHR) (CHR)~ n~-piperidino, -N(R) (CHR) (CHR)~ n~-triazolo, -N(R)(CHR)~ n~-piridino, ou n é de 1-6; R significa hidrogênio, alquila inferior ou alquenila inferior, independentemente entre si, se mais do que um R está presente; R^ 2^ significa nitro ou ciano; R^ 3^significa hidrogênio, alquila inferior, = O, =S, -SR, -S (O)~ 2~-alquila inferior, -(C~ 3~-C~ 2~)cicloalquila ou piperazino, opcionalmente substituído por alquila inferior, ou -CONR~ 2~, -(CHR)~ n~CONR~ 2~, -(CHR)~ n~OR, -(CH~ 2~)~ n~-CF~ 3~- CF~ 3, - (CHR)~ n~OC(O)CF~ 3~, -(CHR)~ n~COOR, -(CHR)~ N~SC~ 6~H~ 5~, em que o grupo fenila pode estar opcionalmente substituído independentemente entre si por um a três grupos alquila inferior, alcóxi inferior, halogênio, nitro ou ciano, -(CHR)~ n~-1,3-dioxo-1,3-diidro-isoindol, -(CHR)~ n~-tetraidro-piran-2-ilóxi ou -(CHR)~ n~S-alquila inferior, ou -NR~ 2~, -NRCO-alquila inferior, -NRCHO -N(R)(CHR)~ n~ CN, -N(R)(CHR)~ n~CF~ 3~, -N(R)(CHR)(CHR)~ n~-OR, -N(R)C (O)(CHR)~ n~O-alquila inferior, -NR(CHR)~ n~-alquila inferior, -NR(CHR)(CHR)~ n~-OR, -N(R)(CHR)(CHR)~ n~-O-fenila, em que o grupo fenila pode estar opcionalmente substituído independentemente entre si por um a três grupos alquila inferior, alcóxi inferior, halogênio, nitro ou ciano, -N(R)(CHR)~ n~-alquenila inferior, -N(R)(CHR)(CHR)~ n~-O-(CHR)~ n~OR, -N(R)(CHR)~ n~C(O)O-alquila inferior, -N(R)(CHR)~ n~C(O)NR-alquila inferior, -N(R)(CH~ 2~)~ n~-2,2-dimetil-[1.3] dioxolano, -N(R)(CHR)(CHR)~ n~morfolino, -N(R)(CHR)~ n~-piridino, -N(R)(CHR)(CHR)~ n~-piperidino, -N(R)(CHR)(CHR)~ n~-pirrolidino, -N(R)(CHR)(CHR)~ n~-O-piridino, -N(R)(CHR)(CHR)~ n~imidazolo, -N(R)(CH)~ n~-CR~ 2~-(CHR)~ n~-OR, -N(R)(CHR)~ n~-CR~ 2~-OR, -N(R)(CHR)~ n~-CHOR-CH~ 2~OR, -N(R)(CHR)~ n~-CHOR-(CHR)~ n~-CH~ 2~OR, ou -OR, -O(CHR)~ n~CF~ 3~, -OCF~ 3~, -O(CHR)(CHR)~ n~-O-fenila, em que o grupo fenila pode estar opcionalmente substituído independentemente entre si por um a três grupos alquila inferior, alcóxi inferior, halogênio, nitro ou ciano, O(CHR)(CHR)~ n~-O- alquila inferior, -O(CHR)~ n~-piridino ou -O(CHR)(CHR)~ n~-morfolino; e R^ 4^ significa hidrogênio, alquila inferior, alquenila inferior ou nitro, ou -OR, -OCF~ 3~, -OCF~ 2~-R, - OCF~ 2~-alquenila inferior, -OCHRF, -OCHF-alquenila inferior, -O(CHR)~ n~CF~ 3~, ou -(CHR)~ n~CHRF, -(CHR)~ n~CF~ 2~R, -(CHR)~ n~CF~ 3~, -(C~ 3~-C~ 6~) ciclo-alquila, -(CHR)~ n~(C~ 3~-C~ 6~)cicloalquila, -(CHR)~ n~CN, -(CHR)~ n~-fenila, em que o grupo fenila pode estar opcionalmente substituído independentemente entre si por um a três grupos alquila inferior, alcóxi inferior, halogênio, nitro ou ciano, -(CHR)(CHR)~ n~OR, -(CHR)~ n~CHORCH~ 2~OR, -(CHR)(CHR)~ n~NR~ 2~, -(CHR)~ n~COOR, -(CHR)(CHR)~ n~OSi-alquila inferior, -(CHR)(CHR)~ n~-OS(O)~ 2~-alquila inferior, -(CH~ 2~)~ n~-CH=CF~ 2~, -CF~ 3~, -CF~ 2~R, -CF~ 2~-alquenila inferior, -CHRF, -CHF-alquenila inferior, -(CHR)~ n~-2,2-dimetil-[1.3] dioxolano, -(CH~ 2~)~ n~-2-oxo-azepan-I-ila, -(CHR)(CHR)~ n~-morfolino, -(CHR)~ n~-piridino, -(CHR)(CHR)~ n~-imidazolo, -(CHR)(CHR)~ n~-triazolo, -(CHR)(CHR)~ n~ -pirrolidino, opcionalmente substituído por (CH~ 2~)~ n~OH, -(CHR)(CHR)~ n~-3-hidróxi-pirrolidino ou -(CHR)(CHR)~ n~-piperidino, ou -NR~ 2~, -N(R)(CHR)~ n~-piridino, -N(R)C(O))-alquila inferior, -N(CH~ 2~CF~ 3~)C(O)O-alquila inferior, -N[C(O))-alquila inferior]~ 2~, -NR-NR-C(O)0-alquila inferior ou -N(R)(CHR)~ n~CF~ 3~, -NRCF~ 3~, -NRCF~ 2~-R, -NRCF~ 2~-alquenila inferior, -NRCHRF, -NRCHF-alquenila inferior; ou está ausente, se X é -N= ou =N-; ou R^ 4^ e R^ 1^ ou R^ 3^ e R^ 4^ estão interligados aos grupos - (CH~ 2~)~ 3-5~-, -(CH~ 2~)~ 2~-N=, -CH=N-N=-, -CH=CH-N=, -NH-CH=CH- ou -NR-CH~ 2~-CH~ 2~- e formam jutamente com os átomos de N e C aos quais eles estão ligados um anel adicional; R^ 5^, R^ 6^ significam hidrogênio, alquila inferior, alcóxi inferior, amino, nitro, -SO~ 2~NH~ 2~ ou halogênio; ou R^ 5^ e R^ 6^ estão interligados ao grupo -O-CH~ 2~-O- e formam juntamente com os átomos de C aos quais eles estão ligados um anel de 5 membros adicionais; R^ 7^, R^ 8^ significam hidrogênio, alquila inferior, alcóxi inferior, amino, nitro ou halogênio, R^ 9^, R^ 10^ significam hidrogênio ou alquila inferior; R^ 11^, R^ 12^ significam hidrogênio, alquila inferior, hidróxi alcóxi inferior, alcoxicarbonilóxi inferior ou alcanilóxi inferior, R^ 13^, R^ 14^ significam hidrogênio, trítio ou alquila inferior; R^ 15^, R^ 16^ significam hidrogênio, trítio, alquila inferior, hidróxi, alcóxi inferior, alcóxi carbonilóxi inferior ou alcanoilóxi inferior ou são juntos um grupo; ou X significa -N=, =N-, =N<, >C= ou =C<; Y significa -N=, =N-, -NH-, -CH=ou =CH-; e a linha tracejada pode ser uma ligação, bem como seus sais farmaceuticamente aceitáveis e sua forma oticamente ativa ou racêmica. Surpreendentemente verificou-se que os compostos da fórmula I são antagonistas em receptores de glutamato metabotrópicos e portanto úteis para o tratamento de doenças relacionadas com estes receptores.
BR0003375-8A 1999-08-06 2000-08-07 1 2 4 5 -tetraidro-benzo{d}azepinas BR0003375A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115557 1999-08-06

Publications (1)

Publication Number Publication Date
BR0003375A true BR0003375A (pt) 2001-03-13

Family

ID=8238742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0003375-8A BR0003375A (pt) 1999-08-06 2000-08-07 1 2 4 5 -tetraidro-benzo{d}azepinas

Country Status (27)

Country Link
US (1) US6218385B1 (pt)
JP (1) JP3260350B2 (pt)
KR (1) KR100390116B1 (pt)
CN (1) CN1146455C (pt)
AR (1) AR025035A1 (pt)
AT (1) ATE254614T1 (pt)
AU (1) AU774485B2 (pt)
BR (1) BR0003375A (pt)
CA (1) CA2314798A1 (pt)
CO (1) CO5180625A1 (pt)
DE (1) DE60006618T2 (pt)
ES (1) ES2209728T3 (pt)
HR (1) HRP20000520A2 (pt)
HU (1) HUP0003112A3 (pt)
ID (1) ID26743A (pt)
IL (1) IL137688A0 (pt)
MA (1) MA26748A1 (pt)
NO (1) NO20003966L (pt)
NZ (1) NZ506096A (pt)
PE (1) PE20010467A1 (pt)
PL (1) PL341890A1 (pt)
RU (1) RU2240317C2 (pt)
SG (1) SG93251A1 (pt)
TR (1) TR200002298A3 (pt)
UY (1) UY26276A1 (pt)
YU (1) YU49700A (pt)
ZA (1) ZA200003927B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2432077C (en) * 2000-12-22 2011-01-18 F. Hoffmann-La Roche Ag Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
NZ540148A (en) * 2002-12-20 2007-11-30 Glaxo Group Ltd Benzazepine derivatives for the treatment of neurological disorders
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
HUE028976T2 (en) * 2003-06-17 2017-02-28 Arena Pharm Inc 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
JP5270167B2 (ja) 2004-12-21 2013-08-21 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンザゼピン塩酸塩の結晶形
CN102631349A (zh) 2004-12-23 2012-08-15 艾尼纳制药公司 5HT2c受体调节剂组合物和使用方法
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP5199997B2 (ja) 2006-04-03 2013-05-15 アリーナ ファーマシューティカルズ， インコーポレイテッド ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
CN101547892B (zh) * 2006-12-05 2014-08-20 艾尼纳制药公司 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
SG10201506870PA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Salts of lorcaserin with optically active acids
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
US8999970B2 (en) 2010-09-01 2015-04-07 Arena Pharmaceuticals, Inc. Administration of an anti-obesity compound to individuals with renal impairment
EP2611433A2 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
KR20150070249A (ko) 2012-10-09 2015-06-24 아레나 파마슈티칼스, 인크. 체중 관리 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
DK0556310T3 (da) * 1990-11-06 1995-08-21 Pfizer Quinazolinderivater til forhøjelse af antitumoraktivitet
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity

Also Published As

Publication number Publication date
AU774485B2 (en) 2004-07-01
ID26743A (id) 2001-02-08
KR100390116B1 (ko) 2003-07-04
NO20003966D0 (no) 2000-08-04
TR200002298A2 (tr) 2001-03-21
MA26748A1 (fr) 2004-12-20
UY26276A1 (es) 2000-10-31
ATE254614T1 (de) 2003-12-15
TR200002298A3 (tr) 2001-03-21
NO20003966L (no) 2001-02-07
US6218385B1 (en) 2001-04-17
HRP20000520A2 (en) 2001-06-30
HU0003112D0 (en) 2000-10-28
PE20010467A1 (es) 2001-04-17
NZ506096A (en) 2002-08-28
DE60006618D1 (de) 2003-12-24
CO5180625A1 (es) 2002-07-30
JP2001089472A (ja) 2001-04-03
IL137688A0 (en) 2001-10-31
HUP0003112A2 (hu) 2002-11-28
SG93251A1 (en) 2002-12-17
ZA200003927B (en) 2001-02-06
PL341890A1 (en) 2001-02-12
DE60006618T2 (de) 2004-09-23
JP3260350B2 (ja) 2002-02-25
RU2240317C2 (ru) 2004-11-20
YU49700A (sh) 2003-04-30
AU4897900A (en) 2001-02-08
CN1146455C (zh) 2004-04-21
AR025035A1 (es) 2002-11-06
ES2209728T3 (es) 2004-07-01
CA2314798A1 (en) 2001-02-06
KR20010082510A (ko) 2001-08-30
CN1283623A (zh) 2001-02-14
HUP0003112A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
BR0003375A (pt) 1 2 4 5 -tetraidro-benzo{d}azepinas
US5225417A (en) Opioid agonist compounds
JP3497164B2 (ja) 二環式フィブリノーゲン拮抗薬
US6476017B2 (en) Compounds activating pharmacological effect of retinoids
KR100443850B1 (ko) 헤테로시클릭 화합물의 도파민-ｄ３ 리간드로서의 용도
RU2000120522A (ru) 1,2,4,5-тетрагидробензо[d]азепины
ES2391472T3 (es) Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
CN101379043A (zh) 取代的2-氨基嘧啶-4-酮、其药物组合物和其在治疗和/或预防Αβ相关病理中的用途
KR20060072142A (ko) Ｃｒｆ 길항제 및 이환식 복소환 화합물
NO300848B1 (no) Nye 2-substituerte indan-2-mercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
JPH10504825A (ja) 二環式化合物
AU2006316256A1 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
CS9101168A2 (en) Pharmaceutical mixtures and method of their active substance production
HUT76058A (en) Naphthylamides as central nervous system agents, pharmaceutical compositions containing the same and process for their preparation
EP0348523A1 (en) Thienodiazepine compounds and their medicinal use
US5672705A (en) Imidazo (1,2-A)pyrazine-4-one derivatives/useful as antagonists of AMPA and NMDA receptors
CA2396277C (en) Condensed azepines as vasopressin agonists
IL179278A (en) Derivatives 8,7,6,5 – Tetrahydro-h4 – Thiano [3,2– d] Azapine and pharmaceutical preparations containing them
CN101360722A (zh) 新颖的2-氨基嘧啶衍生物及其用途
CA2328280C (en) Thienopyrimidines
JPH11505509A (ja) 二環式フィブリノーゲン拮抗薬
IL90973A (en) Medicinal preparations containing a history of benzapine for the treatment of neurological diseases
PL153727B1 (en) A method of 1,2,3,4-tetrahydropirymidinecarboxyl-5 acid derivatives production
AU2002216095B2 (en) Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
KR20020029794A (ko) 바이사이클릭 바소프레신 작용제

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10(VIII), 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.